Overview

Transcranial Ultrasound in Clinical SONothrombolysis

Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
ImaRx Therapeutics
Treatments:
Tissue Plasminogen Activator